Benchmark Reiterates Speculative Buy on Hoth Therapeutics, Maintains $3 Price Target

Benzinga · 10/11 16:22
Benchmark analyst Bruce Jackson reiterates Hoth Therapeutics (NASDAQ:HOTH) with a Speculative Buy and maintains $3 price target.